Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses

Virology

Volumn 274, Issue 1, 2000, Pages 149-164

  Kumar, Anil ^a   Lifson, J D ^b   Silverstein, Peter S ^a   Jia, Fenglan ^a   Sheffer, Darlene ^a   Li, Zhuang ^a   Narayan, Opendra ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; STRAIN DIFFERENCE; VACCINATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034663142     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0444     Document Type: Article

References (73)

1. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
2. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella
3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
4. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1
5. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
6. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
7. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
8. A vaccine for HIV type 1: The antibody perspective
9. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus
10. A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys
11. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity
12. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections
13. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
14. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
15. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection
16. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
17. Disquistions on original antigenic sin. II Proof in lower creatures
18. Neutralizing antibodies administered before but not after virulent SHIV prevent infection in macaques
19. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
20. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
21. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial
22. Candidate AIDS vaccines
23. An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus
24. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
25. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus
26. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus
27. + T cells and AIDS in pig-tailed macaques
28. + T cells, and AIDS
29. + T cell loss and AIDS in rhesus macaques
30. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
31. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
32. Protective immunity induced by live attenuated simian immunodeficiency virus
33. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
34. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial
35. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes
36. Use of Herpesvirus saimiri-immortalized macaque CD4 T cell clones as stimulators and targets of CTL responses in macaque/AIDS models
37. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
38. + T helper cells that secrete IFN-γ and TNF-α
39. + T-helper-cell function
40. Progress in the development of an HIV-1 vaccine
41. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1
42. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
43. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
44. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
45. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
46. Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques
47. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen
48. HIV-1 envelope protein gp120 triggers a Th2 response in mice that shifts to Th1 in the presence of human growth hormone
49. Dissociation of the CD4 and CXCR4 binding properties of human immunodeficiency virus type 1 gp120 by deletion of the first putative alpha-helical conserved structure
50. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection
51. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
52. Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease
53. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
54. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
55. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
56. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
57. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A
58. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop
59. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
60. +-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques
61. Assessing animal models of AIDS
62. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1)vaccine in macaques: Effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
63. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction
64. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay
65. Rubella-specific IgG1 avidity: A comparison of methods
66. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
67. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: Evidence for viral clearance
68. Clinical trials of candidate AIDS vaccines
69. CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120
70. Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated non-human primates
71. Original antigenic sin in ferrets: The response to sequential infections with influenza viruses
72. Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children
73. The antigenic structure of the HIV gp120 envelope glycoprotein